Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nichola Cooper

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|February 27, 2004
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphismsNichola Cooper, Nancy M Heddle, Masja Haas, et al.
Cancer Research|August 6, 2009
Migratory and antigen presentation functions of IFN-producing killer dendritic cellsNourredine Himoudi, Mengyong Yan, Gerben Bouma, et al.
Advances in Therapy|October 27, 2021
Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune ThrombocytopeniaRicardo Viana, Denise D'Alessio, Laura Grant, et al.
Cytotherapy|June 28, 2014
Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2Sophie Derniame, Juliana Perazzo, Fuiyee Lee, et al.
Therapeutic Advances in Hematology|May 17, 2021
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinibNichola Cooper, Ivy Altomare, Mark R Thomas, et al.
Blood Reviews|March 18, 2026
Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapiesDavid J Kuter, Sigbjørn Berentsen, Nichola Cooper, et al.
British Journal of Haematology|November 18, 2024
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extensionNichola Cooper, James B Bussel, Maciej Kaźmierczak, et al.
Blood Advances|August 24, 2021
Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in miceOliver J Herd, Gulab Fatima Rani, James P Hewitson, et al.
BMJ Open|October 21, 2018
Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trialJulie Pell, Rosemary Greenwood, Jenny Ingram, et al.
British Journal of Haematology|January 13, 2021
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopeniaRalph Boccia, Nichola Cooper, Waleed Ghanima, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|February 27, 2004
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphismsNichola Cooper, Nancy M Heddle, Masja Haas, et al.
Cancer Research|August 6, 2009
Migratory and antigen presentation functions of IFN-producing killer dendritic cellsNourredine Himoudi, Mengyong Yan, Gerben Bouma, et al.
Advances in Therapy|October 27, 2021
Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune ThrombocytopeniaRicardo Viana, Denise D'Alessio, Laura Grant, et al.
Cytotherapy|June 28, 2014
Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2Sophie Derniame, Juliana Perazzo, Fuiyee Lee, et al.
Therapeutic Advances in Hematology|May 17, 2021
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinibNichola Cooper, Ivy Altomare, Mark R Thomas, et al.
Blood Reviews|March 18, 2026
Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapiesDavid J Kuter, Sigbjørn Berentsen, Nichola Cooper, et al.
British Journal of Haematology|November 18, 2024
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extensionNichola Cooper, James B Bussel, Maciej Kaźmierczak, et al.
Blood Advances|August 24, 2021
Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in miceOliver J Herd, Gulab Fatima Rani, James P Hewitson, et al.
BMJ Open|October 21, 2018
Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trialJulie Pell, Rosemary Greenwood, Jenny Ingram, et al.
British Journal of Haematology|January 13, 2021
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopeniaRalph Boccia, Nichola Cooper, Waleed Ghanima, et al.
Pageof 15